M. E. Coats

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

R. P. Kinkel, D. L. Cookfair, R. Herndon, 1997, Neurology.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1

C. Granger, R. Herndon, R. Kinkel, 1999, Journal of Neuroimmunology.

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

R. Herndon, R. Rudick, J. Simon, 1998, Neurology.

Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

Jeanelle Sheeder, C. Granger, R. Herndon, 1998 .

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

C. Granger, R. Herndon, R. Kinkel, 1996, Annals of neurology.

Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals.

S. Markey, A. Salazar, M. Heyes, 1992, The Journal of neuropsychiatry and clinical neurosciences.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

C. Granger, R. Kinkel, J. Fischer, 1999, Journal of neuroimmunology.

Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis

R. Herndon, R. Rudick, F. Munschauer, 2005, Multiple sclerosis.